Craft

Deciphera Pharmaceuticals

Stock Price

$25.6

2024-06-10

Market Capitalization

$2.2 B

2024-06-10

Revenue

$163.4 M

FY, 2023

Deciphera Pharmaceuticals Summary

Company Summary

Overview
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. The pipeline includes ripretinib, vimseltinib, rebastinib, and DCC-3116.
Type
Public
Status
Active
Founded
2003
HQ
Waltham, MA, US | view all locations
Website
https://www.deciphera.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Matthew L. Sherman

    Matthew L. Sherman, Executive Vice President, Chief Medical Officer

Operating MetricsView all

Patents (US)

11

Aug, 2017

Patents (Foreign)

47

Aug, 2017

Patent Applications

49

Aug, 2017

LocationsView all

2 locations detected

  • Waltham, MA HQ

    United States

    200 Smith St

  • Lawrence, KS

    United States

    643 Massachusetts St, Suite 200

Deciphera Pharmaceuticals Financials

Summary Financials

Revenue (Q1, 2024)
$45.0M
Gross profit (Q1, 2024)
$42.9M
Net income (Q1, 2024)
($45.1M)
Cash (Q1, 2024)
$91.2M
EBIT (Q1, 2024)
($48.8M)
Enterprise value
$2.1B

Footer menu